Jovan Willford is Chief Executive Officer of Ergomed Group, a specialist global provider of clinical research, consulting and pharmacovigilance services.
Jovan uses data and technology to enable leading service organizations with experiences ranging across payers, providers and the full pharmaceutical spectrum, from clinical development to medical affairs and commercialization.
Most recently, he was CEO and a member of the Board of Directors of Cytel, a provider of statistical software and advanced analytics for clinical trial design, with almost 2,000 professionals across North America, Europe and Asia. He led an operational, commercial and technology transformation generating sustained value for the company. Before Cytel, he was CEO and a board member of Healthgrades and Mercury Healthcare, where he oversaw the separation and sale of two businesses, to Red Ventures and WebMD.
Jovan also served as a Senior Advisor at TPG and several other private equity firms supporting thematic investments in healthcare, including a multi-billion dollar take private of a leading clinical platform. He is a former Independent Director of DNAnexus, a provider of multi-omic data management.
Earlier, he spent nearly a decade as an executive at IQVIA, running the roughly $1.5 billion U.S. Commercial business and a global clinical business across 72 countries. He played a leadership role in the Quintiles–IMS Health merger, which created a $23 billion enterprise, and was a founding member of its real-world evidence businesses in the U.S. and Asia.
Jovan holds an MBA from Northwestern University’s Kellogg School of Management and a BBA from the University of Notre Dame. He grew up in rural Minnesota, which taught him the value of hard work and community and led him to co-found the Pay It Forward Scholarship Fund.



